Document:

EXHIBIT
10.21

 

RESEARCH
AGREEMENT

 

This
Research Agreement (“Agreement”) is made and entered into this 29th day of December, 2016, by and between
One World Cannabis Ltd., a company duly incorporated under the laws of the State of Israel, having its registered office at 7
Imber Street, Petach Tikva, 4951141, Israel, by its authorized representative, Mr. Ziv Turner, CEO (the “Company”)

 

and:

 

Medical
Research Infrastructure Development and Health Services Fund by Chaim Sheba Medical Center, a non-profit organization incorporated
under the laws of the State of Israel, represented by ________________, its authorized representative (the “Fund”);

 

Each
of the parties above may be referred to as “Party” or collectively, as the “Parties.”

 

	Whereas:	The
    Company wishes that the Fund, employing the
    services of Dr. Aviv Barzilay (the “Investigator”)
    carry out the Study, as defined below, in accordance with the terms of this
    Agreement and the Protocol, as defined below; and
	 	 
	Whereas: 	The Fund agrees
    to carry-out the Study, employing the services of the Investigator; and
	 	 
	Whereas:	The Parties to this
    Agreement agree to comply with the terms specified in the Ministry Guidelines, as defined
    below, including without limitation Fonn 4A (to the Guidelines and other
    applicable Israeli laws, rules and regulations; AND
	Whereas	 the Parties
    have executed a master Quality Agreement required pursuant to the MOH Guidelines: GMP (Good Manufacturing Practices) for MPs
    (Investigational Medicinal Products) No. EX-012/01 effective as of 29.12.2016 which
    constitute an integral part of this Agreement.

 

NOW,
THEREFOR, the Parties agree, declare and stipulate as follows:

 

	1.	THE
                                         PREAMBLE AND DEFINITIONS:

 

	 	1.1.	The
                                         Preamble to this Research Agreement and all its addenda constitute an integral part thereof.
                                         The terms specified in the Preamble, which are defined hereinafter, shall be interpreted
                                         according to the meaning ascribed to them hereinafter.
	 	 	 
	 	1.2.	In
                                         addition to terms defined elsewhere in this Agreement or its appendices, the following
                                         terms shall have the meaning ascribed to them hereinafter:
	 	 	 
	 	 	The
                                         “Study”: the clinical trial detailed in the Protocol.

 

The
“Protocol”: The Study plan prepared by the Company numbered 3322-16-SMC\OWC-PS0-01, titled “A Phase I, double
blind, randomized, placebo controlled, maximal dose study to determine the safety, tolerability of Topical cream containing MGC
(Medical Grade Cannabis) in healthy volunteers” attached to this Agreement as Schedule A and constituting an integral part
thereof.

 

	 	The
    “Hospital”: 	Chaim
    Sheba Medical Center.
	 	 	 
	 	The
    “Study Staff”;	The
    personal designated by the Fund for the
	 	 	performance
    of the Study.
	 	 	 
	 	The
    “Study Drug”:	Cannabis.
	 	 	 
	 	The
    “Subject”:	A
    person who is eligible and who has consented to
	 	 	participate
    in the Study.
	 	 	 
	 	“MOH”:	The
    Israeli Ministry of Health.
	 	 	 
	 	“Ministry
    Guidelines:	The
    MOH Guidelines titled “Clinical Trials of Human
	 	 	 
	 	Human	Subjects”
    issued on February 2016, as may
	 	 	 
	 	be	amended
    from time to time or superseded by successor
	 	 	 
	 	Successor	laws,
    rules, regulations or guidelines.

 

    	 

    	 

    

 

	 	“Form
    4A”:	Form
    4A to the Ministry Guidelines titled “Warrants of the Sponsor”, attached to this Agreement as Schedule B and
    constituting an integral part thereof.
	 	 	 
	 	“ICH-GCP”:	IICH
    Harmonized Tripartite Guideline for Good Clinical Practice 135/95, dated 17 July 1996.
	 	 	 
	 	“Helsinki
    Declaration”:	World
    Medical Association Declaration of Helsinki regarding “Ethical Principles for Medical Research Involving Human Subjects”
    as amended and modified from time to time.

 

	2.	PRE-CONDITION:
	 	 
	 	It
    is a condition precedent to the validity of this Research Agreement that this Agreement shall come into effect only after
    approval is received from (i) the Helsinki Committee; and (ii) the Hospital’s Committee for Research Contracts with
    Commercial Companies. The performance of the Study shall commence only after both committees have approved the Study.
	 	 
	3.	THE
    STUDY:

 

	 	3.1.	Compliance.
    The Fund undertakes to perform the Study, employing the services of the Investigator, in compliance with the following:
    (1) the Protocol; (2) the Ministry Guidelines; (3) the instructions and terms specified in the Helsinki Committee’s
    approval; (4) the ICH-GCP; (5) the Helsinki Declarations; (6) the applicable laws, rules and regulations regulating such studies
    which are applicable in Israel; and (7) written instructions and prescriptions issued by the Company and governing the administration
    of the Study Drug (collectively, the “Applicable Laws”). The Fund shall ensure compliance of the Investigator,
    Study Staff and other personnel involved in the performance of the Study on behalf of Fund with all Applicable Laws and the
    provisions of this Agreement.
	 	 	 
	 	 	Should
    any contradiction arise between the Ministry Guidelines, the Protocol or this Agreement, the Ministry Guidelines shall prevail.
	 	 	 
	 	3.2.	Conduct.
    The Study will be conducted in a manner required of a reasonable and prudent clinical investigator or physician.
	 	 	 
	 	3.3	Supply
    of Study Drug. The Company shall provide the Fund, at its sole expense, with the Study Drug and Placebo (when applicable)
    required for the performance of the Study. The Fund shall maintain proper records concerning the administration of the Study
    Drug.

 

 

 

    	2

    	 

    

 

	 	3.4.	Investigator.
    It is agreed by the Parties that the Company is entering into this Agreement based upon the Fund’s representation that
    Dr. Barzilay shall serve as the Investigator and will be responsible for the direction of the Study in accordance with the
    Protocol, applicable Fund policies, generally accepted standards of good clinic practice and all Applicable Laws and regulations.
    All obligations of the Investigator hereunder shall be performed solely by or under the direct supervision of the Investigator.
    In the event the Investigator, for any reason whatsoever, is unable to conduct the Study, or shall cease to be available for
    the performance of the undertakings set forth in this Agreement, the Fund shall use its best efforts to appoint, ·within
    20 (twenty) days, a successor investigator whose identity shall be approved in advance by the Company (the “Successor
    Investigator”). Should the Fund is unable to appoint such Successor Investigator, the Company shall have the sole discretion
    to terminate the Agreement with prior notice. In the event of such early termination, the Company shall pay the Fund the agreed
    Remuneration (as specified in clause 9) solely for Milestones which were fully achieved by the Fund prior to such early termination.
    For the purpose of this Section 3.4, “Milestones”, as detailed in the Protocol.
	 	 	 
	 	3.5.	No
    warranty of results. For the removal of doubt, it is hereby clarified that nothing specified in this Agreement shall be construed
    as a warranty by the Fund that the Study’s results shall be useful in any manner or commercially exploitable.
	 	 	 
	 	3.6.	Informed
    Consent Form (“ICF”). The Fund shall ensure that each and all of the Subjects have given their written informed
    consent to participate in the Study, prior to their participation. The Fund acknowledges and represents that the ICF includes
    and gives effect to all of the elements listed in the Protocol and, in the reasonable opinion of the Fund, any other information
    which should be disclosed therein. The Fund will neither request consent for any Subject, nor allow any Subject to participate
    in the Study, prior to receiving all the necessary approvals detailed in Section 2 above.
	 	 	 
	 	3.7.	Debarment.
    The Fund represents and warrants that, to the best of its knowledge, neither it, nor any of the Study Staff, including the
    Investigator, has been debarred, disqualified or banned from conducting clinical studies.
	 	 	 
	 	3.8.	Storage
    of the Study Drug. The Fund shall store the Study Drug in the Hospital’s Pharmacy according to the Pharmacy’s
    practice and policies and in accordance to the Company’s licenses to use cannabis for medical research, issued by MOH
    - Israel Medical Cannabis Unit (IMCU).
	 	 	 
	 	3.9.	NIH
    Registration. The Company declares and covenants that it had registered the Study in the repository of the National Institute
    of Health (“NIH”) including registration of the Fund and the Hospital as one of the sites performing the Study.
    The confim1ation regarding registration of the Study in the repository of the NIH, as aforesaid, is attached as Schedule
    C to this Agreement and constituting an integral part thereof.
	 	 	 
	 	3.1
    0.	 Biological
    Samples. “Biological Samples” means blood, fluid and/or tissue samples and tangible materials directly
    or indirectly derived from such san1ples, collected from Subjects as may be set forth in the Protocol and as permitted by
    the Informed Consent Form (“ICF”). The Fund, the Investigator and the Study Staff will collect, retain and/or
    use and/or transfer Biological Samples solely as set forth in Applicable Laws, the Protocol, the ICF and as approved by the
    Hospital’s Helsinki Committee. Biological Samples collected for analyses and therapeutic purposes shall be used solely
    for that purpose. Biological Samples will be collected for use in future research only if it was specified in the Protocol,
    the ICF and approved by the ethic committee. To the extent applicable, the Fund shall retain a portion of the Biological Samples
    for future research performed by the Fund provided such is approved by the Hospital’s Helsinki Committee. The Company
    shall pay for any required procedures and/or collection and/or transfer of such Biological San1ples by the Fund and the Investigator.
    Such payment will be as agreed in advance and in writing by the Parties.

 

 

 

    	3

    	 

    

 

	4.	ADVERSE
    EVENT:

 

	 	4.1.	In
    the event that one or more of the Subjects sustain any adverse event related to the Study, the Investigator shall inform the
    Company and/or the Hospital’s Helsinki Committee and/or the Hospital’s management and/or the authorized national
    health authorities, immediately upon occurrence of such adverse event. The Investigator and the Fund are also entitled to
    immediately cease the performance of the Study and report their decision to the Company.
	 	 	 
	 	4.2.	In
    the event that one or more of the Subjects sustain any serious adverse event, the Company undertakes, to the request of the
    Investigator, to break the study medication’s code and immediately inform the Investigator and/or the Fund the content
    of the medication received by each Subject. The Company will also immediately take all measures at its disposal, to evaluate
    the risk to the other patients and will instruct the Investigator which measures to take with regard to such risk.

 

	5.	CONFIDENTIALITY:

 

	 	5.1.	All
    information disclosed by the Company and obtained by the Fund and/or its assistants from the Company in connection with the
    Study (“Confidential Information”) shall be treated as confidential both during the Study and for a period
    of five (5) years following its termination. The Confidential Information shall not be disclosed to any third party without
    prior written approval of the Company, except if requested by law and/or court order and/or the FDA and/or any national regulatory
    authority. This restriction shall not apply to Confidential Information which (i) is, or becomes public domain through no
    act or omission of the Fund and/or (ii) was lawfully obtained by the Fund and/or by the Investigator from another source (iii)
    was already known to the Fund, other than under an obligation of confidentiality, at the time of disclosure by the Company,
    as evidenced in written records; (iv) was independently discovered or developed by the Fund without the use of Confidential
    Information of the Company.
	 	 	 
	 	5.2.	The
    Parties and the Investigator undertake to maintain the confidentiality of all details relating to the Subjects participating
    in the Study. It is hereby agreed that the Fwrd, the Investigator and the Study Staff shall not release any details of the
    identity of the Subjects and the Company undertakes that if, for any reason whatsoever, it should become privy to such details,
    it shall maintain them in strict confidentiality. The Fund agrees to limit its internal disclosure of Confidential Information
    only to those of its employees who need to know such information and who are binding to the terms and conditions included
    in this Agreement. The Parties shall not disclose any Confidential Information to any third party without the prior written
    approval of the other party.

  

    	4

    	 

    

 

	6.	REPORTS
    AND PUBLICATIONS:

 

	 	6.1.	The
    Fund and the Investigator shall promptly and fully disclose to Company in writing all improvements, developments,
    discoveries     and inventions, whether or not patentable, conceived or reduced to practice, either alone or with others, in
    performance of     the Study or relating to Company’s Confidential Information (“Inventions”) and
    according to the License     Agreement that was signed with THM on December 2014. The Fund and the Investigator shall further
    disclose and furnish to Company     all results of the Study and data generated in the performance thereof except Study
    Subject medical records (collectively,     the “Results”) and all reports, records and other material,
    allowable by law that may be prepared by or     on behalf of the Fund or the Investigator or any of the Study Personnel in
    connection therewith or relating to Company’s     Confidential Information (“Reports”). During the
    execution of the Study, the Fund and/or the Investigator     shall provide the Company with: (i) periodical written status
    Reports, which shall inform the Company of the progress of the     Study, major issues, if encountered, and shall summarize
    all the results of the Study during the preceding report period and     provide any other information reasonably requested by
    the Company; (ii) any significant results or discoveries as soon as     practicable after the Fund becomes aware thereof; and
    (iii) a final written report summarizing the results of the Study within     such agreed upon time period as of the end of
    the Study.
	 	 	 
	 	6.2.	Subject
    to clause 5.1-2 above, the Fund agrees to permit representatives of the Company to examine its facilities in order to determine
    their adequacy, validate case reports against original data in its files and monitor work performed to insure its compliance
    with the Protocol. Such inspection shall be coordinated in advance with the Fund, shall take place in times and dates mutually
    agreed upon and shall be conducted in a reasonable manner that shall not interfere with or disturb the work and activities
    being conducted in the Hospital.
	 	 	 
	 	6.3.	The
    Fund and the Investigator shall prepare and maintain records, reports and data as provided in the Protocol and in accordance
    with all applicable laws and regulation.
	 	 	 
	 	6.4.	The
    Fund shall notify and provide the Company with copies of any inquiries, correspondence or communications to or from any governmental
    or regulatory authority related to the Study.
	 	 	 
	 	6.5.	The
    Investigator shall be entitled, consistent with academic standards, to publish the results of the Study, subject to the stipulations
    set forth, provided that such publication does not constitute a violation of Article 5.l above. In the event that the Investigator
    desirers to publish the results as stated in this section, the Company reserves the right to review, amend, modify and edit
    any paper written utilizing data generated from the Study prior to such paper’s presentation or submission for publication
    purposes. In addition, prior to submitting or presenting a manuscript or other materials relating to the Study to a publisher,
    reviewer, or any third party, the Fund shall provide the Company a copy of all such manuscripts and materials, and allow the
    Company 90 days to review and comment, such approval will not be unreasonably withheld. The Fund will give due consideration
    to the Company’s comments and make its best efforts to take them into account. The Fund and Investigator further agree
    to delay any publication in accordance with this section, for an additional 120 days, at the request of the Company, where
    the Company considers such delay necessary for the protection of its intellectual property rights.
	 	 	 
	 	6.6.	If
    the Study is a part of a multi-center study and the Company wishes to publicize a joint publication which includes results
    of all centers, then the Investigator shall not publicize the Study results before the first joint publication, unless such
    publication is not published within 12 month from the completion of the Study at the Hospital.

 

    	5

    	 

    

 

	 	6.7.	The
    Company undertakes to avoid using, directly or indirectly, the name of the Hospital and/or the Fund and/or the Investigator
    and/or any of the Study Staff, in the Company’s commercial publications, as parties recommending the quality and/or
    the effectiveness of the Study Drug.
	 	 	 
	 	6.8.	The
    Company undertakes that should it publicize the results of the Study, it shall publish the results in full and avoid quoting
    matters out of context.

 

	7.	 STUDY
    RESULTS, PROPRIETARY RIGHTS AND INVENTIONS:

 

	 	 	All
    rights to any invention, Reports and Study results, whether or not reduced to practice as a direct result of the performance
    of the Study shall be as detailed in the Research Collaboration and License Agreement dated December 2014 attached hereto
    as Schedule D to this Agreement and constituting an integral part thereof.

 

	8.	TERM
    AND TERMINATION:

 

	 	8.1.	The
    term of this Agreement shall be from the date of its execution by the last Party (subject to approval as conditioned in clause
    2 above, whichever is later) until the Study is either completed according to the Protocol or terminated. It is anticipated
    that the Study should be completed according to the Protocol.
	 	 	 
	 	8.2.	The
    Company retains the right to terminate the Study at any time and for any reason whatsoever, subject to thirty (30) days prior
    written notice. In the event such early termination occurs, or in the event of any early termination whatsoever, which is
    not due to a breach of this Agreement by the Fund or by the Investigator or by any of the Fund’s employees, agents or
    officers, the Company shall pay the Fund all the following payments:
	 	 	 
	 	8.3.	The
    costs of non-cancelable items.
	 	 	 
	 	8.4.	The
    payment of the agreed Remuneration which shall be prorated according to Article 9 and Schedule E.
	 	 	 
	 	8.5.	The
    full Storage Fee, as defined bellow
	 	 	 
	 	8.6.	The
    rights and duties under Article 5 (Confidentiality), Article 6 (Reports and Publications) and Article 7 (Study
    results, Proprietary Rights and Inventions), shall survive the termination or expiration of this Agreement for any reason.

 

	9.	REMUNERATION:

 

	 	9.1.	In
    return for the Fund’s obligations hereunder, the Company undertakes to pay the Fund the amounts specified in the payment
    schedule listed in Schedule E attached to this Agreement and constituting an integral part thereof (the “Remuneration”).
    Notwithstanding anything to the contrary in Schedule E, the Company shall pay the Fund, within seven (7) days from the
    date of execution hereof, an advance payment of 15% (fifteen percent) of the total Remuneration.
	 	 	 
	 	9.2.	The
    Company shall pay the Fund, for each 12-month period, 3,500 NIS (three thousand and five hundred NIS), plus 15% overhead in
    return for the storage of the Study Drug in the Pharmacy (“Storage Fee”). In addition, the Company shall pay any
    other fees, as specified in Schedule D for the preparation and/or sterilization and/ or any other care required to be performed
    by the pharmacy.
	 	 	 
	 	9.3.	The
    Fund shall provide the Company with a receipt for each installment paid.
	 	 	 
	 	9.4.	The
    Company shall pay the costs of medical treatment required by any Subject for any illness or condition caused by the performance
    of the Study and/or the Study Drug and/or procedure required by the Protocol, provided that the Study is administered in accordance
    with the Protocol and without negligence or willful misconduct, or failure to act on the part of the Fund, Study Staff or
    the Investigator.

 

    	6

    	 

    

  

	 	9.5.	The
    Fund and Company agree that if the Fund received reimbursement from any healthcare program or other insurance of the Subject,
    the Fund will not seek reimbursement of such medical expenses from the Company. If Fund receives payment from any health care
    or insurance program for medical expenses already reimbursed by Company hereunder, Fund shall promptly notify Company and
    reimburse Company for such payments.

 

	10.	CLAIMS,
    LIABILITY AND INSURANCE:

 

	 	l0.1.	The
    Company shall bear sole responsibility, pursuant to the applicable law and this Agreement, and bear any payment and/or compensation
    and/or liability for any damage whatsoever caused, directly or indirectly, to any person, as a result of the performance of
    the Study and/or a derivative thereof (the: “Damages”) unless such Damages arose out of the negligence,
    willful misconduct of the Fund or any on its behalf.
	 	 	 
	 	10.2.	The
    Company shall indemnify and hold harmless, the Fund, the Hospital, the Study Staff, the Investigator and their employees and/or
    agents and/or officers and/or representatives involved in the performance of the Study (the “Beneficiaries”)
    from and against any and all claims, demands, causes of action and suits of whatsoever kind or nature based on damages
    claimed to have been caused as a result of the following: (i) the performance of the Study and/or (ii) any procedures prescribed
    in the Protocol and/or pertaining to the Study and/or (iii) the use by the Company of the results of the Study and/or (iv)
    the administration, use marketing or consumption of the product to which the results relate (the “Loss”). The
    above indemnity shall not apply where:

 

	 	10.2.1.	The
    Loss was caused as a result of negligence, malfeasance or willful misconduct of the Fund and/or the Investigator and/or the
    Study Staff; or
	 	 	 
	 	10.2.2.	The
    Loss was caused as a result of a failure, by the Fund and/or the Investigator and/or the Study Staff, to comply with the terms
    of the Protocol or other written instruction of the Company concerning use of the Study Drug or device and/or this Agreement
    and/or failure to comply with any applicable laws.

 

	 	10.3.	Subject
    to that stated above in this Section 10, the Company shall pay all expenses associated with any proceedings taking place as
    a result of a complaint and/or legal claim submitted by any person in respect of the Loss.
	 	 	 
	 	10.4.	For
    the purpose of the Indemnity pursuant to section 10.2 above the Fund undertakes as follows: (i) The Fund shall notify the
    ·company, within 15 (fifteen) days from the day the Fund acquired such knowledge, of any claim, or injury relating to
    the Study; (ii) the Beneficiaries shall permit the Company to assume full responsibility for the investigation of, preparation
    for, and defense of, any claim for which indemnification is being sought; and (iii) the Beneficiaries agree to cooperate with
    Company in the defense of any claim or suit relating to the Loss and permit Company to have the exclusive right to control
    the defense and/or settlement of any such claim or suit, including without limitation the right to select- defense counsel,
    provided that Company shall not have the right to settle any such claim or suit without the prior written consent of the Fund
    unless such settlement only involves the payment of money and the Beneficiaries are given an unconditional release from all
    liability by the claimant therein.

 

    	7

    	 

    

 

	 	10.5.	Without
    derogating from its liabilities stated above, the Company shall at its own expense insure its liability pursuant to this Agreement,
    including this clause 10 for the term as follows: (i) if the insurance policy is on claims occurred basis - for the term of
    this Agreement or (ii) if the insurance policy is on claims made basis -for the period of this Agreement plus an additional
    period until the limitation term of any Loss have elapsed according to the Israeli Limitation Law. Such insurance shall be
    in reasonable amounts which shall not be less than $3,000,000 (three million) USD and on reasonable terms in the circumstances,
    having regard, in particular, to the nature of the Study and the Study Drug. The named insured under such insurance shall
    be the Company and the Beneficiaries. The policy or policies so issued shall include a “cross-liability” provision
    pursuant to which the insurance is deemed to be separate insurance for each named insured (without right of subrogation as
    against any of the insured under the policy, or any of their representatives, employees, officers, directors or anyone in
    their name) and shall further provide that the insurer will be obliged to notify each insured in writing at least 30 (thirty)
    days in advance of the expiry or cancellation of the policy or policies. The Company undertakes that such insurance shall
    include any future amendments to the Protocol. 
	 	 	 
	 	10.6.	This
    clause 10 shall survive the termination of this Agreement and remain in full force and affect.
	 	 	 
	 	10.7.	The
    Fund and its officers, employees, directors and agents and the clinical studies conducted at the Hospital are covered under
    professional liability insurance in the framework of an insurance arrangement, in accordance with applicable law and regulation
    and as customarily maintained by governmental hospitals in Israel.

 

	11.	Disclaimers:

 

	 	11.1.	Under
    no circumstances the liability of the Beneficiaries to the Company under or arising out of this Agreement whether for breach
    of contract, in tort (including, but not limited to, negligence) or otherwise shall exceed in aggregate a sum equal to the
    remuneration.
	 	 	 
	 	11.2.	Company’s
    indemnification liability pursuant to this Agreement shall be limited to the amounts of insurance purchased by Company pursuant
    to Section 10.5 above.

 

	12.	LAW
    AND VENUE:

 

	 	 	Any
    dispute between the parties to this Agreement, including its breach and/or its implementation and/or its termination, shall
    be decided exclusively by the competent court of law in Tel-Aviv, Israel which shall have exclusive jurisdiction and the law
    that shall apply shall be the statutes and laws of the State of lsrael.

 

	13.	MISCELLANEOUS:

 

	 	13.1.	Superiority.
    Should any contradiction arise between the provisions of this Agreement and any of its appendices (excluding the Protocol),
    including the payment schedule and/or any other document executed in connection with this Agreement, save for Form 4A, the
    provisions of this Agreement shall prevail.
	 	 	 
	 	13.2.	Non-employment.
    For the purpose of this Agreement, the Fund and/or the Study Staff and/or the Investigator shall be deemed an independent
    contractor and shall not be considered a partner, agent, employee or representative of the Company.
	 	 	 
	 	13.3.	Good
    Faith. Both parties shall be under a duty to act in good faith in the performance and enforcement of this Agreement.

 

    	8

    	 

    

 

	 	13.4.	Continuing
    Obligations. The rights and obligations of each of the Parties hereto under any provision of this Agreement, which is
    expressly or by implication intended to survive beyond the term of this Agreement, including but not limited to those provisions
    relating to Publication Rights, Confidentiality, Indemnification and Insurance, and Intellectual Property Rights, shall survive
    the expiration or termination of this Agreement for any reason.
	 	 	 
	 	13.5.	Notices.
    Except as otherwise provided in this Agreement, all notices permitted or required by this Agreement shall be in writing
    and shall be deemed to have been duly served (i) upon personal delivery (ii) upon facsimile transmission (receipt of which
    has been orally confirmed by the recipient) or (iii) Seven (7) business days after deposit,postage prepaid, return receipt
    requested, if sent by registered mail and addressed to the address of the parties first above stated or in accordance with
    such other address information as the party to receive notice may provide in writing to the other party in accordance with
    the above notice provisions. Any notice given by any other method will be deemed to have been duly served upon receipt thereof.
	 	 	 
	 	13.6.	Assignment.
    This Agreement is personal to the Parties and may not be assigned without the prior written consent of the other Party.
    Notwithstanding the above, the Fund shall be entitled to assign its rights and obligations hereunder to any legal entity established
    in connection with or for the benefit of the Hospital, provided however, that such legal entity shall assume in writing
    all the obligations under this Agreement
	 	 	 
	 	13.7.	Captions.
    Any paragraph or other captions are inserted for convenience only and shall not be considered a part of or affect the
    interpretation or construction of any of the provisions of this Agreement.
	 	 	 
	 	13.8.	Waivers.
    No course of dealing in respect of, nor any omission or delay in the exercise of, any right, power, or privilege by either
    Party shall operate as a waiver thereof, nor shall any single or partial exercise thereof preclude any further or other exercise
    thereof or of any other, as each such right, power, or privilege may be exercised either independently or concurrently with
    others and as often and in such order as each party may deem expedient.
	 	 	 
	 	13.9.	Entire
    Agreement; Amendments. This Agreement, including, without limitation, its schedules, contains the entire agreement of
    the Parties with respect to its subject matter. No oral or prior written statements or representations not incorporated herein
    shall have any force or effect, nor shall any part of this Agreement be amended, supplemented, waived or otherwise modified
    except in a writing signed by both Parties.
	 	 	 
	 	13.10.	Severability.
    If any provision of this Agreement is determined by a court of competent jurisdiction to be invalid, illegal, or unenforceable,
    that determination shall not affect any other provision of this Agreement, and each such other provision shall be construed
    and enforced as if the invalid, illegal, or unenforceable provision were not contained herein.

 

 

 

    	9

    	 

    

 

 

    	10

    	 

    

 

I,
the undersigned, Dr. Barzilay, hereby declare and confirm that I read and understood the Agreement, I agree to be appointed as
the Investigator of the Study on behalf of the Fund, and I undertake to comply with all the conditions, provisions, instructions
and stipulations of the Agreement.

 

The
Investigator

 

December
29, 2016

 

 

 

 

    	11EX-10.1

 Exhibit 10.1 

FOURTH AMENDED AND RESTATED INVESTMENT ADVISORY AGREEMENT 

BETWEEN 
 GLADSTONE
COMMERCIAL CORPORATION 
 AND 

GLADSTONE MANAGEMENT CORPORATION 
  

 
 This Fourth
Amended and Restated Investment Advisory Agreement Between Gladstone Commercial Corporation and Gladstone Management Corporation (this “Agreement”) is made this 10th day of
January 2017, by and between Gladstone Commercial Corporation, a Maryland corporation (the “Company”), and Gladstone Management Corporation, a Delaware corporation (the “Adviser”). 

Whereas, this Agreement shall amend and restate that certain Third Amended and Restated Investment Advisory Agreement between the Company and
the Adviser, dated July 12, 2016. 
 Whereas, the Company is a real estate investment trust organized primarily for the purpose of
investing in and owning net leased industrial and commercial rental property and selectively making long-term mortgage loans collateralized by industrial and commercial property; 

Whereas, the Adviser is an investment adviser that has registered under the Investment Advisers Act of 1940; and 

Whereas, the Company desires to retain the Adviser to furnish investment advisory services to the Company on the terms and conditions
hereinafter set forth, and the Adviser wishes to be retained to provide such services. 
 Now, therefore, in consideration of the premises
and for other good and valuable consideration, the parties hereby agree as follows: 
 1. Duties of the Adviser. 

(a) The Company hereby employs the Adviser to act as the investment adviser to the Company and to manage the investment and reinvestment
of the assets of the Company, subject to the supervision of the Board of Directors of the Company, for the period and upon the terms herein set forth, (i) in accordance with the investment objective, policies and restrictions that are set forth
in the Company’s Annual Reports on Form 10-K, filed with the Securities and Exchange Commission from year to year, pursuant to Section 13 of the Securities and Exchange Act of 1934 and
(ii) during the term of this Agreement in accordance with all applicable federal and state laws, rules and regulations, and the Company’s charter and by-laws. Without limiting the generality of the
foregoing, the Adviser shall, during the term and subject to the provisions of this Agreement, (i) determine the composition of the portfolio of the Company, the nature and timing of the changes therein and the manner of implementing such
changes; (ii) identify, evaluate and negotiate the structure of the investments made by the Company; (iii) close and monitor the Company’s investments; (iv) determine the real property, securities and other assets that the
Company will purchase, retain, or sell; (v) perform due diligence on prospective portfolio companies; and (vi) provide the Company with such other investment advisory, research and related services as the Company may, from time to time,
reasonably require for the investment of its funds. The Adviser shall have the discretion, power and authority on behalf of the Company to effectuate its investment decisions for the Company, including the execution and delivery of all

 
documents relating to the Company’s investments and the placing of orders for other purchase or sale transactions on behalf of the Company. In the event that the Company determines to
acquire debt financing, the Adviser will arrange for such financing on the Company’s behalf, subject to the oversight and approval of the Company’s Board of Directors. If it is necessary for the Adviser to make investments on behalf of the
Company through a special purpose vehicle, the Adviser shall have authority to create or arrange for the creation of such special purpose vehicle and to make such investments through such special purpose vehicle. 

(b) The Adviser hereby accepts such employment and agrees during the term hereof to render the services described herein for the
compensation provided herein. 
 (c) The Adviser is hereby authorized to enter into one or more
sub-advisory agreements with other advisers (each, a “Sub-Adviser”) pursuant to which the Adviser may obtain the services of the Sub-Adviser(s) to assist the Adviser in fulfilling its responsibilities hereunder. Specifically, the Adviser may retain a Sub-Adviser to recommend specific investments based
upon the Company’s investment objective and policies, and work, along with the Adviser, in structuring, negotiating, arranging or effecting the acquisition or disposition of such investments and monitoring investments on behalf of the Company,
subject to the oversight of the Adviser and the Company. The Adviser, and not the Company, shall be responsible for any compensation payable to any Sub-Adviser. Any
sub-advisory agreement entered into by the Adviser shall be in accordance with the requirements of applicable federal and state law. 

(d) The Adviser shall for all purposes herein provided be deemed to be an independent contractor and, except as expressly provided or
authorized herein, shall have no authority to act for or represent the Company in any way or otherwise be deemed an agent of the Company. 

(e) The Adviser shall keep and preserve for a reasonable period any books and records relevant to the provision of its investment
advisory services to the Company and shall specifically maintain all books and records with respect to the Company’s portfolio transactions and shall render to the Company’s Board of Directors such periodic and special reports as the Board
may reasonably request. The Adviser agrees that all records that it maintains for the Company are the property of the Company and will surrender promptly to the Company any such records upon the Company’s request, provided that the Adviser may
retain a copy of such records. 
 (f) The Adviser has adopted and implemented written policies and procedures reasonably designed to
prevent violation of the Federal Securities laws by the Adviser. The Adviser has provided the Company, and shall provide the Company at such times in the future as the Company shall reasonably request, with a copy of such policies and procedures.

 2. Company’s Responsibilities and Expenses Payable by the Company. 

All investment professionals of the Adviser and their respective staffs, when and to the extent engaged in providing investment advisory and
management services hereunder, and the compensation and routine overhead expenses of such personnel allocable to such services, will be provided and paid for by the Adviser and not by the Company. The Company will bear all other costs and expenses
of its operations and transactions, including (without limitation) those relating to: organization and offering; expenses incurred by the Adviser payable to third parties, including agents, consultants or other advisors (such as independent
valuation firms, accountants and legal counsel), in monitoring financial and legal affairs for the Company and in monitoring the Company’s investments and performing due diligence on its real estate or prospective portfolio

  
  

2 | Page 

 
companies; interest payable on debt, if any, incurred to finance the Company’s investments; offerings of the Company’s common or preferred stock and other securities; investment
advisory and management fees; administration fees, if any, payable under the existing administration agreement between the Company and Gladstone Administration, LLC (the “Administrator”), dated January 1, 2007 (the
“Administration Agreement”); fees payable to third parties, including agents, consultants or other advisors, relating to, or associated with, evaluating and making investments; transfer agent and custodial fees; federal and
state registration fees; all costs of registration and listing the Company’s shares on any securities exchange; federal, state and local taxes; independent Directors’ fees and expenses; costs of preparing and filing reports or other
documents required by the Securities and Exchange Commission; costs of any reports, proxy statements or other notices to stockholders, including printing costs; the Company’s allocable portion of the fidelity bond, directors and officers and
errors and omissions liability insurance, and any other insurance premiums; direct costs and expenses of administration, including printing, mailing, long distance telephone, copying, secretarial and other staff, independent auditors and outside
legal costs; and all other expenses incurred by the Company or the Administrator in connection with administering the Company’s business, including payments under the Administration Agreement between the Company and the Administrator based upon
the Company’s allocable portion of the Administrator’s overhead in performing its obligations under the Administration Agreement, including rent and the allocable portion of the cost of certain of the Company’s personnel, including,
but not limited to, its chief compliance officer, treasurer, chief financial officer, general counsel, secretary, chief valuation officer, and their respective staffs. 

3. Compensation of the Adviser. 
 The
Company agrees to pay, and the Adviser agrees to accept, as compensation for the services provided by the Adviser hereunder, a base management fee (“Base Management Fee”) and an incentive fee (“Incentive
Fee”) as hereinafter set forth. The Company shall make any payments due hereunder to the Adviser or to the Adviser’s designee as the Adviser may otherwise direct. 

(a) Base Management Fee. 

The Base Management Fee shall equal 1.50% (thus, 0.375% per quarter) of Total Equity (as defined below) per annum, which shall be calculated
and payable quarterly in arrears in cash. “Total Equity” shall equal: (i) total stockholders’ equity plus total mezzanine equity, as reported on the Company’s balance sheet (“Reported
Equity”) for the quarter, before the Base Management Fee and Incentive Fee have been recorded, adjusted to exclude (ii) any unrealized gains and losses that have impacted Reported Equity, and also adjusted to exclude (iii) any
one-time events and certain non-cash items; provided that, with respect to subsection (iii) each item shall be approved by the Company’s Compensation
Committee. For the avoidance of doubt, the Total Equity as defined in this Agreement, may be greater or less than the Reported Equity. 

(b) Incentive Fee. 
 The
Incentive Fee is an amount, not less than zero, equal to the product of 15% and: 
  

	 	(i)	the Company’s Core FFO (defined below) for the quarter, minus 

  

	 	(ii)	 the product of (A) 8.0% (thus, 2.0% per quarter) multiplied by (B) (i) the Reported Equity for the quarter
before the Incentive Fee has been recorded, adjusted to exclude (ii) any unrealized gains and losses that have impacted 

  
  

3 | Page 

	 	
Reported Equity, and also adjusted to exclude (iii) any one-time events and certain non-cash items, provided
that with respect to subsection (iii) each item shall be approved by the Company’s Compensation Committee 

 In the
event that the calculation delineated in Section 3(b) yields an Incentive Fee for a particular quarter that exceeds by greater than 15% the average quarterly Incentive Fee paid during the trailing four quarters (averaged over the number of quarters
any Incentive Fee was paid), then such Incentive Fee shall equal 115% of such trailing average quarterly Incentive Fee. 
 (c)
“Core FFO”, a non - Generally Accepted Accounting Principles in the United States (“GAAP”) measure, shall be defined as GAAP net income (loss) available to
common stockholders, computed in accordance with GAAP, excluding the Incentive Fee, depreciation and amortization, any realized and unrealized gains, losses or other non-cash items recorded in net income
(loss) available to common stockholders for the period, and one-time events pursuant to changes in GAAP. 

(d) Capital Gain Fee. 
 The
Capital Gain Fee is a capital gains-based incentive fee that shall be determined and payable in arrears as of the end of each fiscal year (or, for an abbreviated time period as of the effective date of any termination of this Agreement). The
Capital Gain Fee shall for any applicable time period shall equal: (i) 15% of the cumulative aggregate realized capital gains minus the cumulative aggregate realized capital losses, minus (ii) the aggregate Capital Gains Fees paid in previous
time periods. Realized capital gains and realized capital losses are calculated by subtracting from the sales price of a property: (a) any costs incurred to sell such property, and (b) the current gross value of the property (meaning
the property’s original acquisition price plus any subsequent non-reimbursed capital improvements thereon). A Capital Gain Fee shall only be paid for an applicable time period to the extent that
doing so would not violate any distribution payment covenant in a then-existing line of credit to the Company. For avoidance of doubt, the Capital Gain Fee shall only be payable for applicable time periods when the cumulative aggregate realized
capital gains exceeded the cumulative aggregate realized capital losses. 
 4. Limitations on the Employment of the Adviser. 

The services of the Adviser to the Company are not exclusive, and the Adviser may engage in any other business or render similar or different
services to others including, without limitation, the direct or indirect sponsorship or management of other investment based accounts or commingled pools of capital, however structured, having investment objectives similar to those of the Company,
so long as its services to the Company hereunder are not impaired thereby, and nothing in this Agreement shall limit or restrict the right of any manager, partner, officer or employee of the Adviser to engage in any other business or to devote his
or her time and attention in part to any other business, whether of a similar or dissimilar nature, or to receive any fees or compensation in connection therewith (including fees for serving as a director of, or providing consulting services to, one
or more of the Company’s portfolio companies, subject to applicable law). So long as this Agreement or any extension, renewal or amendment remains in effect, the Adviser shall be the only investment adviser for the Company, subject to the
Adviser’s right to enter into sub-advisory agreements. The Adviser assumes no responsibility under this Agreement 

  
  

4 | Page 

 
other than to render the services called for hereunder. It is understood that directors, officers, employees and stockholders of the Company are or may become interested in the Adviser and its
affiliates, as directors, officers, employees, partners, stockholders, members, managers or otherwise, and that the Adviser and directors, officers, employees, partners, stockholders, members and managers of the Adviser and its affiliates are or may
become similarly interested in the Company as stockholders or otherwise. 
 5. Responsibility of Dual Directors, Officers or Employees. 

If any person who is a manager, partner, officer or employee of the Adviser or the Administrator is or becomes a director, officer or employee
of the Company and acts as such in any business of the Company, then such manager, partner, officer or employee of the Adviser or the Administrator shall be deemed to be acting in such capacity solely for the Company, and not as a manager, partner,
officer or employee of the Adviser or the Administrator or under the control or direction of the Adviser or the Administrator, even if employed by the Adviser or the Administrator. 

6. Limitation of Liability of the Adviser: Indemnification. 

The Adviser (and its officers, managers, partners, agents, employees, controlling persons, members and any other person or entity affiliated
with the Adviser, including without limitation the Administrator) shall not be liable to the Company for any action taken or omitted to be taken by the Adviser in connection with the performance of any of its duties or obligations under this
Agreement or otherwise as an investment adviser of the Company, and the Company shall indemnify, defend and protect the Adviser (and its officers, managers, partners, agents, employees, controlling persons, members and any other person or entity
affiliated with the Adviser, including without limitation its general partner and the Administrator, each of whom shall be deemed a third party beneficiary hereof) (collectively, the “Indemnified Parties”) and hold them
harmless from and against all damages, liabilities, costs and expenses (including reasonable attorneys’ fees and amounts reasonably paid in settlement) incurred by the Indemnified Parties in or by reason of any pending, threatened or completed
action, suit, investigation or other proceeding (including an action or suit by or in the right of the Company or its security holders) arising out of or otherwise based upon the performance of any of the Adviser’s duties or obligations under
this Agreement or otherwise as an investment adviser of the Company. Notwithstanding the preceding sentence of this Section 6 to the contrary, nothing contained herein shall protect or be deemed to protect the Indemnified Parties against or
entitle or be deemed to entitle the Indemnified Parties to indemnification in respect of, any liability to the Company or its security holders to which the Indemnified Parties would otherwise be subject by reason of willful misfeasance, bad faith or
gross negligence in the performance of the Adviser’s duties or by reason of the reckless disregard of the Adviser’s duties and obligations under this Agreement. 

7. Termination of Agreement. 
 This
Agreement may be terminated at any time upon 120 days’ prior written notice, after the vote of at least two-thirds of the independent directors of the Company for any reason (“Termination
Without Cause”). In the event of Termination Without Cause, a termination fee equal to two times the sum of the average annual Base Management Fee and Incentive Fee earned by the Adviser during the
24-month period prior to the effective date of such termination (the “Termination Fee”). 

  
  

5 | Page 

 This Agreement may be terminated effective upon 30 days prior written notice by the vote of at
least two-thirds of the independent directors of the Company without payment of the Termination Fee if the termination is for Cause. “Cause” shall occur if (i) the Adviser breaches any material
provision of this Agreement and such breach shall continue for a period of 30 days after written notice thereof specifying such breach and requesting that the same be remedied in the such 30-day period,
(ii) there is a commencement of any proceeding relating to the Adviser’s bankruptcy or insolvency, including an order for relief in an involuntary bankruptcy case or the Advisor authorizing or filing a voluntary bankruptcy petition
(iii) the Adviser dissolves, (iv) the Adviser commits fraud against the Company or misappropriates or embezzles funds of the Company and in each case a court of competent jurisdiction enters a judgement against the Adviser; provided,
however, that if any of the actions or omissions described in this clause (iv) are caused by an employee, personnel and/or officer of the Adviser and the Adviser commences action against such person to cure the damage caused by such actions
or omissions within 90 days of the Adviser’s actual knowledge of its commission or omission, the Company shall not have the right to terminate this Agreement for Cause. 

The Adviser may terminate this Agreement effective upon 60 days prior written notice of termination to the Company in the event that the
Company shall default in the performance or observance of any material term, condition or covenant contained in this Agreement and such default shall continue for a period of 30 days after written notice thereof specifying such default and
requesting that the same be remedied in such 30-day period. The Company is required to pay to the Adviser the Termination Fee if the termination of this Agreement is made pursuant to this paragraph. 

The provisions of Section 6 of this Agreement shall remain in full force and effect, and the Adviser and its representatives shall remain
entitled to the benefits thereof, notwithstanding any termination or expiration of this Agreement. Further, notwithstanding any termination or expiration of this Agreement as aforesaid, the Adviser shall be entitled to any amounts owed under
Section 3 through the effective date of termination or expiration. 
 8. Assignment. 

This Agreement is not assignable or transferable by either party hereto without the prior written consent of the other party. 

9. Amendments. 
 This Agreement may be
amended by mutual consent. 
 10. Notices. 

Any notice under this Agreement shall be given in writing, addressed and delivered or mailed, postage prepaid, to the other party at its
principal office. 
 11. Entire Agreement; Governing Law. 

This Agreement contains the entire agreement of the parties and supersedes all prior agreements, understandings and arrangements with respect
to the subject matter hereof. This Agreement shall be construed in accordance with the laws of the State of Delaware. 

  
  

6 | Page 

 12. Effectiveness. 

All fees and calculations contemplated hereunder for the quarter ending December 31, 2016, shall be calculated as if this Agreement was
effective as of October 1, 2016. 
  
  

In Witness Whereof, the parties hereto have caused this Agreement to be duly executed on the date above written. 

 

			
	Gladstone Commercial Corporation
		
	By:	 	 /s/ Bob Cutlip

		 	 Bob Cutlip
 President

	
	Gladstone Management Corporation

  

			
	By:	 	 /s/ David Gladstone

		 	 David Gladstone
 Chairman and Chief Executive
Officer

  
  

7 | Page

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00265-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00265-of-00352.parquet"}]]